Finance

Beta
Lists
4016:TADAWUL
Middle East Pharmaceutical Inds Co SJSC
SAR 58.50
-0.68%
(-0.40) 1D
Jun 7, 1:53:39 PM GMT+3  ·   SAR
All symbols
SymbolPriceChange% Change
Generating top insights for 4016...
Open
SAR 58.50
High
SAR 58.90
Low
SAR 58.20
Mkt. cap
2.05B
Avg. vol.
180.27K
Volume
38.46K
Dividend
2.36%
Quarterly dividend
SAR 0.35
Ex-dividend date
Mar 30, 2026
P/E ratio
19.59
52-wk high
SAR 79.09
52-wk low
SAR 53.89
EPS
SAR 2.99
Shares outstanding
20.24M
No. of employees
731
Open
SAR 58.50
High
SAR 58.90
Low
SAR 58.20
Mkt. cap
2.05B
Avg. vol.
180.27K
Volume
38.46K
Dividend
2.36%
Quarterly dividend
SAR 0.35
Ex-dividend date
Mar 30, 2026
P/E ratio
19.59
52-wk high
SAR 79.09
52-wk low
SAR 53.89
EPS
SAR 2.99
Shares outstanding
20.24M
No. of employees
731
News stories
From sources across the web
About Middle East Pharmaceutical Inds Co SJSC
CEOMohamed Maher Al Ghannam
Employees731
Founded1998
HeadquartersRiyadh, Riyadh Province, Saudi Arabia
SectorPharmaceutical industry
Websiteavalonpharmaceutical.com
Previous reportsAll values in SAR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SAR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
117.66M
107.95M
137.52M
130.13M
Cost of goods sold
44.31M
45.81M
47.32M
49.78M
Cost of revenue
44.31M
45.81M
47.32M
49.78M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
45.37M
50.78M
43.26M
48.09M
Operating expense
45.56M
51.48M
43.77M
50.05M
Total operating expenses
89.87M
97.29M
91.08M
99.83M
Operating income
27.78M
10.66M
46.43M
30.30M
Other non operating income
-
-
-
-
EBT including unusual items
27.05M
9.82M
45.93M
29.13M
EBT excluding unusual items
27.05M
9.82M
45.89M
29.13M
Income tax expense
2.24M
1.54M
1.41M
2.23M
Effective tax rate
8.29%
15.69%
3.07%
7.67%
Other operating expenses
184.76K
-147.78K
-109.44K
-54.06K
Net income
24.81M
8.28M
44.52M
26.90M
Net profit margin
21.09%
7.67%
32.38%
20.67%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-731.86K
-844.49K
-562.26K
-1.16M
Net interest expenses
-731.86K
-844.49K
-562.26K
-1.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
30.78M
13.78M
49.70M
33.47M
Gain or loss from assets sale
-
-40.87K
-55.44K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer